Avacopan vs lower-dose steroids for new vasculitis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Newly diagnosed with ANCA-associated vasculitis (a rare autoimmune disease affecting blood vessels)
- Positive blood test for ANCA antibodies (PR3 or MPO)
- No prior treatment for this vasculitis
- No severe kidney disease or lung bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This trial tests a new treatment called CT1192 for a type of blood vessel inflammation called ANCA-associated vasculitis. It is for people whose standard treatments have not worked or whose disease has come back. The goal is to see if CT1192 is safe and helps control the disease.
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.